Featured Article
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer among Caucasians, with estimates of approximately 1.1 million new cases annually in the US [1,2].
While outcomes are favorable for most patients, and the vast majority of cSCCs are cured with complete excision, an estimated 3–7% of patients develop metastases that lead to
significant morbidity and mortality [2–4]. Thus, early diagnosis and treatment of cSCCs, and their premalignant precursors, is crucial to minimize morbidity and conserve healthcare
resources.






